Reduction of Platelet Activity Markers in Type II Hypercholesterolemic Patients by a HMG-CoA-Reductase Inhibitor

This publication has 17 references indexed in Scilit:

• Interactions of Platelets, Macrophages, and Lipoproteins in Hypercholesterolemia: Antiatherogenic Effects of HMG-CoA Reductase Inhibitor Therapy
  Journal of Cardiovascular Pharmacology, 1998
• Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets
  British Journal of Clinical Pharmacology, 1997
• High-dose fluvastatin and bezafibratecombination treatment for heterozygous familial hypercholesterolemia
  The American Journal of Cardiology, 1995
• Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group.
  Published by Wiley ,1994
• Direct detection of activated platelets and platelet-derived microparticles in humans
  Blood, 1990
• HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
  New England Journal of Medicine, 1988
• Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation
  Blood, 1987
• Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase.
  Circulation, 1986
• Platelet formation of 12-hydroxyeicosatetraenoic acid and thromboxane B2 is increased in type IIA hypercholesterolemic subjects
  Atherosclerosis, 1986
• Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia.
  Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1986